Revisiting biomarker discovery by plasma proteomics
-
- Philipp E Geyer
- Department of Proteomics and Signal Transduction Max Planck Institute of Biochemistry Martinsried Germany
-
- Lesca M Holdt
- Institute of Laboratory Medicine University Hospital LMU Munich Munich Germany
-
- Daniel Teupser
- Institute of Laboratory Medicine University Hospital LMU Munich Munich Germany
-
- Matthias Mann
- Department of Proteomics and Signal Transduction Max Planck Institute of Biochemistry Martinsried Germany
書誌事項
- 公開日
- 2017-09
- 権利情報
-
- http://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.15252/msb.20156297
- 公開者
- Springer Science and Business Media LLC
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p> Clinical analysis of blood is the most widespread diagnostic procedure in medicine, and blood biomarkers are used to categorize patients and to support treatment decisions. However, existing biomarkers are far from comprehensive and often lack specificity and new ones are being developed at a very slow rate. As described in this review, mass spectrometry ( <jats:styled-content style="fixed-case">MS</jats:styled-content> )‐based proteomics has become a powerful technology in biological research and it is now poised to allow the characterization of the plasma proteome in great depth. Previous “triangular strategies” aimed at discovering single biomarker candidates in small cohorts, followed by classical immunoassays in much larger validation cohorts. We propose a “rectangular” plasma proteome profiling strategy, in which the proteome patterns of large cohorts are correlated with their phenotypes in health and disease. Translating such concepts into clinical practice will require restructuring several aspects of diagnostic decision‐making, and we discuss some first steps in this direction. </jats:p>
収録刊行物
-
- Molecular Systems Biology
-
Molecular Systems Biology 13 (9), 942-, 2017-09
Springer Science and Business Media LLC
